Associate Professor
Weill Cornell Medicine
Disclosure(s): AbbVie: DSMB participant; bioMerieux: Grant/Research Support; Merck: Grant/Research Support; SNIPRBiome: Grant/Research Support
Dr. Michael Satlin an infectious diseases physician and Associate Professor of Medicine and of Pathology and Laboratory Medicine at Weill Cornell Medicine. He is Director of the Infectious Diseases Clinical Research Unit and Member of the Transplantation-Oncology Infectious Diseases Program at Weill Cornell. He completed medical school at the University of Virginia and internal medicine residency and infectious diseases fellowship at NewYork-Presbyterian Hospital/Weill Cornell. He also obtained a Master’s Degree in Clinical and Translational Investigation at Weill Cornell. His research focuses on the epidemiology, prevention, and treatment of multidrug-resistant Gram-negative infections, with a focus on immunocompromised hosts. He is Co-Chair of the Breakpoint Working Group of the Clinical and Laboratory Standards Institute’s (CLSI) Subcommittee on Antimicrobial Susceptibility Testing and a Member of the Infectious Diseases Society of America’s (IDSA) guidance panel for the treatment of antibiotic-resistant Gram-negative infections. He is also Vice Chair of the Gram-Negative Subcommittee of NIAID’s Antibacterial Resistance Leadership Group and Senior Editor of Journal of Antimicrobial Chemotherapy-Antimicrobial Resistance.